PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 8, 2015Journal of Clinical Oncology1,203 citations

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

View Full Paper
JHJunzo HamanishiMMMasaki MandaiTITakafumi Ikeda

Key Points

Key points are not available for this paper at this time.

Abstract

This study, to our knowledge, is the first to explore the effects of nivolumab against ovarian cancer. The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hamanishi et al. (2015) studied this question.

synapsesocial.com/papers/69d957a45e5bcb4e3b835ab1https://doi.org/10.1200/jco.2015.62.3397
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan2001 · 1,238 citations
  2. 2Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary2007 · 153 citations
  3. 3HLA Class I Expression on Human Ovarian Carcinoma Cells Correlates with T-Cell Infiltrationin Vivoand T-Cell Expansionin Vitroin Low Concentrations of Recombinant Interleukin-21996 · 73 citations
  4. 4Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade2002 · 3,233 citations
  5. 5Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel2010 · 91 citations